Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st March 2026
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 9.7% | -5.6% | -5.6% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 9.7% | -5.6% | -5.6% |
Prosper Stars & Stripes generated -5.6% net return in Q1 2026, underperforming the Russell 2000's 0.9% return amid volatile market conditions driven by Middle East geopolitical crisis and AI investment boom bifurcation. The fund maintains 48% average net exposure in small cap long/short strategy. Key contributors included Modine Manufacturing, benefiting from AI data center thermal management demand, and nLIGHT, positioned in directed energy defense applications. Both positions were exited upon reaching price targets. Short book performed well with Via Transportation and Asana contributing positively. Manager sees compelling setup for small caps with earnings growth forecasted at 25% in 2026, marking recovery from pandemic overhang. Portfolio repositioned opportunistically amid geopolitical uncertainty, persistent inflation from tariffs, and energy price doubling due to Strait of Hormuz closure. Forward outlook cautious on macro risks but optimistic on small cap fundamentals and structural advantages from reduced competition in the space.
Small cap long/short strategy focused on identifying mispriced opportunities in structurally inefficient small cap universe, with concentrated positions in 30-50 longs and shorts based on fundamental research and differentiated narratives.
Market backdrop has shifted considerably with futures now reflecting possibility of rate hikes rather than cuts, driven by resilient labor market, higher inflation, and elevated oil prices. Geopolitical risk remains elevated with unclear resolution to Iran conflict. First quarter earnings acceleration has been extraordinary, providing counterweight to inflationary and geopolitical headwinds. Manager believes process is well-suited to current environment for identifying durable alpha-generating opportunities.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| May 29 2026 | 2026 Q1 | AEHR, ASAN, BLFS, ITRI, LASR, MOD, VIA, VPG | AI, defense, energy, geopolitics, Long/Short, Manufacturing, small cap | - | Small cap long/short fund delivered -5.6% in volatile Q1 marked by Middle East crisis and AI boom. Exited profitable positions in Modine and nLIGHT at targets while shorts contributed positively. Small cap earnings acceleration of 25% forecasted for 2026 supports thesis despite geopolitical and inflation headwinds. Portfolio repositioned for better risk/reward opportunities. |
| Jan 28 2026 | 2025 Q4 | ATI, EAT, GTLB, INOD, KTB, META, MSFT, PDFS, RVTY, SEAT, SITM, STUB, TKNO | AI, alpha, healthcare, Long/Short, semiconductors, small caps, value | - | Small cap long/short fund delivered +9.9% in 2025 through disciplined stock selection in structurally inefficient markets. Strong contributors from AI-beneficiary SiTime and aerospace materials provider ATI. Outlook remains constructive with monetary and fiscal tailwinds supporting small cap outperformance in 2026. Strategy focuses on mispriced opportunities with recurring revenue models and competitive moats while managing risks through balanced long/short positioning. |
| Nov 11 2025 | 2025 Q3 | AGYS, BRBR, GDYN, JACK, KLG, PKE, RAL, TATT, TRNS | aerospace, AI, defense, healthcare, Long/Short, small caps, technology | TATT | Strong Q3 performance driven by aerospace and defense investments amid structural market opportunities in small caps. Manager sees favorable setup for 2026 with Fed easing, AI productivity gains, and broadening earnings recovery. Key risks include trade tensions and job market softening. Increased healthcare exposure while shorting consumer companies vulnerable to changing preferences and GLP-1 disruption. |
| Aug 19 2025 | 2025 Q2 | AGYS, AZTA, BIO, EXPO, FTAI, HELE, KRMN, LASR, MGNI, PACK, SPHR, TATT, TKNO | aerospace, AI, Biotechnology, defense, Long/Short, Rate Cuts, small caps, tariffs | - | Strong Q2 recovery with +9.6% returns driven by broad-based long book success, particularly in digital advertising and hospitality software. Fund maintains aerospace and defense focus while increasing healthcare exposure. Constructive outlook supported by pro-business fiscal policies, expected rate cuts, and improving small cap fundamentals after years of cyclical headwinds. |
| Apr 24 2025 | 2025 Q1 | AMSC, COLD, FLYW, FTRE, HELE, KRMN, KRNT, LH, MTLS, NSIT, PAYX, PYRC, RGEN, RHP, SARO, TLN, TRS, XMTR | Biotechnology, defense, energy, Long/Short, Onshoring, small caps, tariffs, Trade Policy | - | Fund returned -9.7% in Q1 as aggressive tariff policy derailed small cap recovery thesis, with policy uncertainty reaching crisis levels. Portfolio positioned for cyclical improvement was hurt by sector rotation and individual stock selection. Manager adjusted risk profile while maintaining focus on structural inefficiencies in small caps, expecting volatility to create opportunities despite macro headwinds from trade disruption. |
| Dec 31 2024 | 2024 Q4 | ALGM, BE, BELFB, BIRK, CCB, ENS, FTAI, KNF, MIR, NCNO, ORION, PACK, PKX, PRTY, RGLD, SRAD, STAA, TALEN, TEKK | healthcare, industrials, Long/Short, mid cap, small cap, technology | - | Stars & Stripes outperformed Russell 2000 in December through strong short positioning despite long book weakness. The fund maintains 46% net exposure in US mid/small caps, benefiting from healthcare shorts and select consumer positions while facing headwinds in industrials and technology holdings amid shifting Fed rate expectations. |
| Nov 7 2024 | 2024 Q3 | BIO, BLFS, CRS, DOCS, FLT, FND, FOXF, NR, PCT, RGEN, SHC, UPWK, WEX | aerospace, healthcare, infrastructure, interest rates, Long/Short, Recession, semiconductors, small cap | - | Small cap long/short fund outperformed in volatile Q3, delivering -2.0% versus Russell 2000's -5.1% decline. Strong performance from aerospace and infrastructure holdings, successful short exits. Economic resilience continues but faces headwinds from persistent inflation, global weakness, and geopolitical tensions. Portfolio positioned to capitalize on rolling industry cycles and small cap inefficiencies while maintaining disciplined risk management. |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2026 Q1 |
AIAI investment boom driving GDP growth with 17% business spending growth. Manager sees AI as defining the current business cycle with implications for productivity, job market, and inflation. Views current AI capex cycle as historically significant though not anomalous by past technology boom standards. |
Data Centers Semiconductors Infrastructure Productivity |
DefenseDefense spending remains a strategic priority with directed energy systems offering compelling economics. Manager invested in nLIGHT for laser applications and York Space Systems for satellite infrastructure, though exited both positions after hitting targets or due to visibility concerns. |
Space Defense Electronics Government IT | |
EnergyGeopolitical conflicts in Middle East caused oil prices to roughly double from pre-conflict levels due to Strait of Hormuz closure. Energy was the positive outlier in Russell 2000, rising 37.9% in Q1. Energy crises historically precede economic slowdowns. |
Oil Geopolitical Risk Supply Disruption | |
Small CapsSmall cap earnings growth forecasted to rise 25% in 2026 followed by 10%+ in 2027, marking sustained recovery. Small caps have underperformed large caps for much of past decade but showing improvement. Manager sees structural advantages in small cap universe due to reduced competition and inefficiencies. |
Earnings Value Market Inefficiency | |
RoboticsConvergence of robotics market growth with manufacturing recovery creating opportunities. Vishay Precision Group working with multiple humanoid robotics manufacturers. Humanoid robotics industry expected to begin scaling and grow substantially, expanding addressable markets. |
Automation Industrial Machinery Manufacturing | |
| 2025 Q4 |
AIAI investment cycle continues driving economic growth and market gains. Revenue per employee increasing at large AI companies supports the investment thesis. AI spend levels comparable to past tech investment expansions. |
Artificial Intelligence Data Centers Investment Cycle Productivity Technology |
Small CapsSmall caps expected to grow at better pace than large caps in 2026. Long period of underperformance relative to large caps may end with better profit growth. Strong start to 2026 supported by easing monetary conditions. |
Russell 2000 Underperformance Profit Growth Valuation Recovery | |
SemiconductorsSemiconductor industry experiencing high growth from normal demand and AI buildout. PDF Solutions positioned at nexus of strong industry trends with e-probe business seeing order pickup for 3-D semiconductor structures. |
Chip Demand 3D Structures Supply Chain Yields Growth | |
HealthcareHealthcare positioned for catch-up growth after years of below-trend performance. Government spending expected to increase relative to feared cuts. Many companies signaling improvement in revenue growth outlook. |
Life Sciences Research Spending Recovery Growth Diagnostics | |
RatesFed lowered overnight rate by 25 basis points in December, third cut in 2025. Futures market anticipates one or two more cuts in 2026. Three cuts in 2025 likely to be added to in 2026 as monetary policy tailwind. |
Federal Reserve Rate Cuts Monetary Policy Easing Tailwind | |
| 2025 Q3 |
AerospaceThe fund sees significant opportunities in aerospace companies, particularly those benefiting from maintenance cycles and growth in auxiliary power units. TAT Technologies is positioned to capture market share in the B737 and A320 family aircraft markets with a total addressable market of $2.5 billion. |
MRO APU Aircraft Defense OEM |
Defense SpendingDefense-related investments are benefiting from increased procurement needs, particularly in missile systems. Park Aerospace has exposure to Patriot missile systems where the US Army is looking to increase procurement by 4x from current depleted levels. |
Patriot Missiles Military Procurement Defense | |
AIAI is viewed as a major productivity driver that has contributed approximately 1% to GDP growth. The manager expects AI investments to lead to improved labor productivity and margin expansion, though acknowledges the full benefits are yet to be realized. |
Productivity GDP Automation Technology Margins | |
Small CapsThe manager believes small caps remain attractive with supportive valuations and improving earnings outlook for 2026. Historical cycles suggest extended periods of relative outperformance when trends shift, supported by monetary easing and broadening earnings growth. |
Valuations Earnings Outperformance Cycles Monetary | |
GLP1GLP-1 weight loss medications are disrupting traditional food and beverage consumption patterns, reducing average calorie intake by 16-39%. This creates challenges for legacy food companies and restaurants while creating opportunities for protein-focused businesses. |
Weight Loss Consumption Food Disruption Protein | |
| 2025 Q2 |
DefenseDefense spending has strengthened with clearer priorities, particularly in missile and drone defense reflecting modern warfare evolution. The fund identified nLIGHT as a beneficiary of increased spending on laser-based anti-missile and anti-drone systems, which offer cost-efficient solutions with low cost per shot and unlimited magazine capacity. |
Defense Spending Laser Technology Missile Defense Drone Defense Golden Dome |
AerospaceThe fund consistently invests in aerospace given its steady growth, attractive margins for value-added suppliers, regulatory barriers to entry, and emphasis on quality. Recent investments include TAT Technologies for MRO services in commercial aerospace, capitalizing on growing demand while incumbents hesitate to expand capacity. |
MRO Commercial Aviation Auxiliary Power Units Aerospace Components Aviation Services | |
BiotechnologyBioprocessing is entering a period of sustained recovery after years of underperformance. The fund increased exposure through positions like Bio-Rad Laboratories and Alpha Teknova, believing many headwinds are now reflected in valuations and the sector is positioned for recovery. |
Bioprocessing Life Science Tools Drug Development Commercial Stage Sartorius | |
AIAI presents both opportunities and threats across sectors. While large companies benefit from AI spending boom accounting for up to half of GDP growth, AI also creates disruption risks for consulting firms through systematic reference capabilities and increased time efficiency in background work. |
Artificial Intelligence AI Spending Expert Consulting Automation Efficiency | |
AdvertisingDigital advertising is experiencing a long tail transition from linear to streaming TV. Magnite, as the leading independent supply-side platform, benefits from this shift and potential DOJ antitrust remedies against Google, which could increase market share opportunities significantly. |
Digital Advertising Connected TV Supply Side Platform Streaming Antitrust | |
Trade PolicyTariff shock on Liberation Day created unprecedented uncertainty with rates so high the situation escalated from trade war to trade embargo. The ever-changing tariff narrative continues to yield surprises, though effects on businesses have been limited as companies proactively factor costs into outlooks. |
Tariffs Trade War Trade Embargo Economic Uncertainty Business Impact | |
| 2025 Q1 |
Trade PolicyThe administration announced tariff rates far higher than anticipated on April 2nd, reverting the U.S. to protectionist policies not seen for 100 years. Policy uncertainty measures shot to near record highs, creating large negative impacts on stock, bond and currency markets. Businesses face increased costs from higher tariffs and supply chain adjustments. |
Tariffs Protectionism Supply Chain Policy Uncertainty Trade War |
Small CapsSmall caps significantly underperformed large caps during the quarter, entering a bear market with a peak-to-trough decline just shy of 30%. The fund believes small caps had a better opportunity to improve relative to the market due to cyclical recovery expectations and sustained underperformance. |
Russell 2000 Underperformance Bear Market Cyclical Recovery Valuation | |
DefenseThe fund has invested in several defense stocks that will benefit from stability in overall defense spending and shifting priorities that emphasize the navy and modernizing weapon systems. Examples include Karman Holdings which supplies subsystems for space, missiles, and hypersonic weapons. |
Defense Spending Modernization Space Missiles Navy | |
OnshoringOne goal of trade policy is to onshore manufacturing of key goods. Investment announcements have been made to produce more goods in the U.S., though the investment needed will take years to have impact and require skilled workforce. Companies like Xometry and Kornit Digital benefit from localized production trends. |
Manufacturing Domestic Production Supply Chain Localization Investment | |
Energy TransitionTalen Energy's crown jewel Susquehanna nuclear power plant signed a long-term power purchase agreement with Amazon Web Services for 960 MW. Given demand for clean energy and AI datacenters, nuclear assets have scarcity value in the PJM market with limited new generation capacity expected by 2030. |
Nuclear Clean Energy Data Centers Power Purchase Agreement Grid Capacity | |
BiotechnologyThe life science tools industry experienced headwinds from post-COVID de-stocking but shows green shoots with Repligen's pharma and consumable orders increasing mid-to-high teens. Near-record 64 new drug approvals in 2024 suggest the post-COVID hangover is ending. |
Life Science Tools Drug Development Bioprocessing Post-COVID Recovery FDA Approvals | |
| 2024 Q3 |
SemiconductorsThe semiconductor industry has experienced a 20%+ decline in revenues similar to past industry cycles, following supply shortages that drove demand to unsustainably high levels during the pandemic. The manager sees opportunities in this rolling cycle as the industry normalizes from previous boom-bust dynamics. |
Semiconductor Cycle Supply Chain Cyclical Recovery Industry Normalization Revenue Decline |
AerospaceCommercial aerospace benefits from barriers to entry created by regulation, long production cycles and high switching costs, enabling value-added suppliers to earn high margins. The industry faces a long duration expansion cycle due to high travel demand and unusual supply depression during recent years. |
Commercial Aviation Supply Chain Barriers to Entry Travel Demand Production Cycles | |
Infrastructure SpendingU.S. infrastructure spending is rising, creating high demand for composite mats and related services. The manager expects this trend to continue, supporting companies that provide infrastructure-related products and services with positive operating leverage. |
Infrastructure Government Spending Composite Materials Construction Operating Leverage | |
BiotechnologyHealthcare sector growth is supported by aging population and improving treatment options, but faces pressure from higher interest rates affecting funding and broad inventory destocking. The pandemic encouraged aggressive spending that continues to normalize, creating opportunities as conditions improve. |
Healthcare Aging Demographics Medical Devices Funding Pressure Inventory Destocking |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | Fund Letters | Christopher Hillary | TATT | TAT Technologies Ltd. | Industrials | Aerospace & Defense | Bull | NASDAQ | Aerospace, aftermarket, Apus, Defense, growth, MRO, valuation | Login |
| TICKER | COMMENTARY |
|---|---|
| MOD | Modine Manufacturing Company (MOD) was the top contributor in our long book in the first quarter. The company has been undergoing a classic industrial transformation story. Through a series of acquisitions and divestitures, we believe management has repositioned Modine's deep thermal engineering expertise away from slower growth end-markets like automotive and toward higher-growth, structurally advantaged markets such as AI data centers. With the announced spin-off of its Performance Technologies segment, Modine will become a pure play Climate Solutions business with a focus on data center cooling, commercial HVAC, and refrigeration. Over the past three years, Modine's data center business has delivered annual revenue growth in excess of 60% per year. This growth has driven EBITDA margins from 9% in FY2023 to an expected 17% by FY2027. Hyperscalers are expected to spend roughly $725 billion on AI capex in FY2026, and the chips powering this buildout require advanced thermal management solutions like those Modine provides. Consistent with our valuation discipline, we exited the position in March as the EV/EBITDA multiple reached 20x, which we viewed as fair value. |
| LASR | nLIGHT (LASR) was the second-largest contributor in our long book in the quarter. The company is one of the leading providers of high-power lasers for mission-critical directed energy (DE) and optical sensing applications. The U.S. Department of War has made directed energy a strategic priority, supporting sustained investment in both research and deployment. With more than 450 patents and a U.S.-based semiconductor fabrication facility, nLIGHT is a vertically integrated supplier of semiconductor and fiber lasers to the DoW. This positioning has driven a meaningful shift in its revenue mix: defense has grown from 18% of sales in FY2018 to 70% today. The company's defense segment delivered 60% year-over-year growth in FY2025. Competition remains limited due to the technical complexity of coherent beam combination (CBC) technology. Notably, nLIGHT has demonstrated a 300kW-class high-energy laser under the DoD's HELSI program, exceeding program performance objectives. Directed energy systems offer compelling economics for the DoW. The cost per use is estimated to be between $1 and $10 compared to $13 million for a THAAD interceptor or $4 million for a Patriot missile. We initiated our position in May 2025 and exited in early April upon hitting our price target. |
| VIA | Via Transportation (VIA) was the largest contributor in our short book in the first quarter. The company went public in September 2025, positioning itself as the operating system for public transit, offering routing algorithms, scheduling tools, fleet management software, and a passenger-facing application. We initiated our short position shortly after its IPO based on the view that the market was mischaracterizing a labor-intensive transit contractor as a high-margin software company. In FY2025, Via reported gross margins of 40%, well below the 70%+ typical of pure-play software companies. Importantly, the company's growth remains tied to driver hours and vehicle utilization, rather than scalable, low-marginal-cost software deployment. We also believe there are potential structural risks in the business model. Approximately 90% of revenue is derived from government clients, exposing Via to contracting cycles, budget constraints, and political dynamics. Our due diligence further indicated limited pricing power, highlighted by a recent contract renegotiation with LA Metro. We continue to maintain a short position in Via. |
| ASAN | Asana (ASAN) was the second-largest contributor in our short book in the quarter. The company provides an enterprise work management software platform designed to help teams coordinate, track, and execute projects across functions to manage work efficiently. We believe the market overstates the durability and differentiation of Asana's product, which is simply a workflow and task management tool. The company exhibits several of our key short criteria, including decelerating growth, lack of profitability, and intense competition. Asana operates in a crowded landscape, facing established players such as Microsoft, Salesforce, Notion, and Smartsheet, among others. Revenue growth has slowed to below 10%, and dollar-based net revenue retention has fallen below 100%, indicating contraction within the existing customer base. Asana has attempted to reposition its narrative, describing itself as a system of action for work, built for the Agentic Enterprise, emphasizing collaboration between humans and AI agents. We view this shift as aspirational, with limited evidence in the underlying financials to support a meaningful inflection in growth or product differentiation. Finally, the broader emergence of advanced AI agents presents an additional structural risk. As workflows become increasingly automated, the long-term value proposition of traditional SaaS coordination layers is likely to come under pressure. We exited Asana when it reached our target. |
| AEHR | Aehr Test Systems (AEHR) was the largest detractor in our short book in the quarter. The company provides equipment for testing, burn-in, and stabilization of semiconductor devices at the wafer level. While this method offers theoretical efficiency advantages, it remains a niche solution with limited broad-based adoption. Our view is supported by several factors. First, the company exhibits significant customer concentration, with ON Semiconductor accounting for approximately 80% of revenue. Second, the Aehr use case is predominantly confined to a single use case: silicon carbide (SiC) devices used in electric vehicle applications. Third, the company's financial performance reflects this narrow exposure: Aehr generated approximately $59 million in revenue in FY2025, down 11% year-over-year, and consensus expectations point to a further 17% decline in FY2026 to roughly $50 million. This is a contrast to management's emphasis on growth opportunities in areas such as AI and silicon photonics. Taken together, the combination of declining revenue, lack of profitability, and limited success expanding beyond its core SiC testing niche for EVs suggests to us that Aehr's business reality is weaker than the optimistic assumptions required by its high multiples. However, either our thesis is misplaced, or our timing premature, and we adhered to our risk management discipline and covered the position. |
| VPG | Vishay Precision Group (VPG) is a direct beneficiary of both trends. The company manufactures sensors, measurement systems, and weighing solutions – a business that was pressured for several years by weakness in the general industrial economy. That headwind is now reversing as a manufacturing recovery took hold earlier this year and appears likely to continue absent a significant economic shock. Vishay Precision's first quarter results (reported May 12th) reinforced this thesis. The company posted a book-to-bill above 1.0x for the sixth consecutive quarter and laid out a medium-term outlook that reflects an ongoing transformation of the business: revenue growth accelerating towards 10% and operating margins more than doubling to approximately 20%, compared to single digits over the past two years. Demand has broadened across multiple end-markets, including military and space, semiconductors, and data centers. Beyond the cyclical recovery, there is a compelling emerging growth narrative. Vishay Precision is actively working with multiple humanoid robotics manufacturers. Current revenues from this channel are modest, but the humanoid robotics industry is expected to begin scaling later this year and grow substantially thereafter, a thematic tailwind that could meaningfully expand the company's addressable market. We continue to see meaningful upside from current levels, supported by the prospect of sales and earnings beats against a favorable thematic backdrop. Assuming the stock re-rates toward 5x sales and 25x EV/EBITDA on 2028 estimates, multiples consistent with companies demonstrating sustained revenue and earnings growth, implying a potential share price of approximately $135. |
| BLFS | We actively monitor our Focus List to revisit compelling ideas when risk/reward becomes favorable. This discipline drove both our decision to reinvest in Vishay Precision and to add BioLife Solutions (BLFS) back into the portfolio. BioLife has had an eventful history as a public company. The company's former CEO pursued an acquisition strategy that we believe diluted rather than enhanced the company's core strengths. Current CEO Roderick de Greef has largely reversed that course, divesting most of those businesses and refocusing the company on its highest-quality products. The result is a cleaner, more focused business, better positioned to capitalize on the underlying growth in its end markets. The cornerstone of the business has always been biopreservation media, a product with a high growth rate and exceptional margins. This is an excellent example of a 'picks & shovel' business in healthcare. The media is used by customers in the manufacturing of cell-based therapies, an end-market expected to grow over 20% annually over the next five years. The recent underperformance of healthcare and life science tools stocks brought BioLife's valuation to a level where we again see a compelling long opportunity. With 20%-plus top-line growth and meaningful margin expansion driving rapid EBITDA growth, we believe the stock offers a compelling risk/reward from current levels. |
| ITRI | Roubaix L/S has delivered strong short-side performance this year. Our strategy targets both idiosyncratic and thematic short opportunities, and one area of focus has been companies that are benefiting from the surge in electrical grid investment. Itron (ITRI), the smart metering company, caught our attention because of its failure to participate in the utility spending tailwind as many bulls had expected. Over the past several years, Itron has pursued an aggressive acquisition strategy aimed at expanding its addressable market and diversifying its revenue base. However, results have consistently disappointed. We believe that the disconnect is structural rather than cyclical. Utilities typically treat metering upgrades as routine maintenance rather than transformative capital investment, which is a very different narrative to the one Itron has been selling. End-markets are project-driven, lumpy by nature, and we believe they are unlikely to deliver the sustained growth cadence implied by the company's valuation. With AI-driven infrastructure buildout generating enthusiasm around utility spending, the gap between market expectations and Itron's likely reality became difficult to ignore. The most recent quarter confirmed our thesis: Itron missed again, citing the same lumpiness and timing issues. We consider the stock overvalued relative to its industrial peers given revenue growth near flat, EBITDA margins in the mid-teens, and an EV/EBITDA multiple above 11x. We see further downside as we believe the market will be increasingly frustrated by the persistent gap between management's optimistic outlook and the company's actual results. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||